It has been proposed that hyperproliferative skin lesions (keratoacanthomas) and in some cases SCC in BRAF inhibitor-treated patients were caused by pERK upregulation in wild-type BRAF cells [20]–[22], with a high RAS mutation frequency [30]. This evidence concerns the gene BRAF and keratoacanthoma.